A phase i study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium

Journal of Pediatric Hematology/Oncology

Volumn 36, Issue 6, 2014, Pages 458-463

  Raetz, Elizabeth A ^a   Morrison, Debra ^a   Romanos Sirakis, Eleny ^b   Gaynon, Paul ^c   Sposto, Richard ^c,d   Bhojwani, Deepa ^e   Bostrom, Bruce C ^f   Brown, Patrick ^g   Eckroth, Elena ^d   Cassar, Jeannette ^d   Malvar, Jemily ^d   Buchbinder, Aby ^h   Carroll, William L ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h Enzon Incorporated   (United States)

Author keywords

antisense; relapsed ALL; survivin

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; CYTARABINE; DOXORUBICIN; EZN 3042; MESSENGER RNA; METHOTREXATE; PREDNISONE; SURVIVIN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BIOLOGICAL ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CHILD; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOLITIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; LIVER DISEASE; METABOLIC DISORDER; MONOTHERAPY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; HUMANS; INFANT; INHIBITOR OF APOPTOSIS PROTEINS; MALE; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; RNA, MESSENGER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905108842     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182a8f58f     Document Type: Article

References (25)

1. Reismuller B, Attarbaschi A, Peters C, et al. Long-Termoutcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria-A population-based report of the Austrian Berlin-Frankfurt-Munster (BFM) Study Group. Br J Haematol. 2009;144:559-570.
2. Roy A, Cargill A, Love S, et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia-lessons from the United Kingdom R2 trial. Br J Haematol. 2005;130:67-75.
3. Einsiedel HG, von Stackelberg A, Hartmann R, et al. Longterm outcome in children with relapsed ALL by risk-stratified salvage therapy: Results of trial acute lymphoblastic leukemiarelapse study of the Berlin-Frankfurt-Munster Group 87. J Clin Oncol. 2005;23:7942-7950.
4. Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: A Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28:648-654.
5. Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: A Children's Oncology Group study. Leukemia. 2008;22:2142-2150.
6. Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): An open-label randomised trial. Lancet. 2010;376:2009-2017.
7. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol. 2008;26:3971-3978.
8. Saarinen-Pihkala UM, Heilmann C, Winiarski J, et al. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: Role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol. 2006;24:5750-5762.
9. Tallen G, Ratei R, Mann G, et al. Long-Term outcome in children with relapsed acute lymphoblastic leukemia after timepoint and site-of-relapse stratification and intensified shortcourse multidrug chemotherapy: Results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28:2339-2347.
10. Bhojwani D, Kang H, Moskowitz NP, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: A Children's Oncology Group study. Blood. 2006;108:711-717.
11. Hogan LE, Meyer JA, Yang J, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood. 2011;118:5218-5226.
12. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science. 2008;322:1377-1380.
13. Yang JJ, Bhojwani D, Yang W, et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood. 2008;112:4178-4183.
14. Fangusaro JR, Caldas H, Jiang Y, et al. Survivin: An inhibitor of apoptosis in pediatric cancer. Pediatr Blood Cancer. 2006; 47:4-13.
15. Kanwar RK, Cheung CH, Chang JY, et al. Recent advances in anti-survivin treatments for cancer. Curr Med Chem. 2010;17:1509-1515.
16. Kelly RJ, Lopez-Chavez A, Citrin D, et al. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer. 2011;10:35.
17. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999;23:387-388.
18. Morrison DJ, Hogan LE, Condos G, et al. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia. 2012;26:271-279.
19. Park E, Gang EJ, Hsieh YT, et al. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood. 2011;118:2191-2199.
20. Tyner JW, Jemal AM, Thayer M, et al. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia. 2012;26:623-632.
21. Sapra P, Wang M, Bandaru R, et al. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids. 2010;29:97-112.
22. Tolcher AW, Patnaik A, Papadopoulos KP, et al. Results of a phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin mRNA antagonist, administered with or without docetaxel in adult patietns with advanced solid tumors or lymphoma. Proceedings of the 102nd Annual Meeting of AACR. 2011:LB-409 (abstract). Orlando, Florida, April 5, 2011.
23. Mansoor M, Melendez AJ. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Bio. 2008;2:275-295.
24. Yu RZ, Grundy JS, Geary RS. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol. 2013;9:169-182.
25. Bhatla T, Wang J, Morrison DJ, et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood. 2012;119:5201-5210.